Monday, November 23, 2020

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Cancer shared this article with you from Inoreader
Conditions:   Chemotherapy;   Anti-pd-1 Antibody;   Cervical Neuroendocrine Carcinoma;   Adverse Drug Event;   Recurrent Cervical Carcinoma;   Advanced Cervical Carcinoma;   Objective Response Rate Intervention:   Drug: Drug therapy Sponsor:   Lei Li Recruiting (Source: ClinicalTrials.gov)
View on the web
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...